Alibaba-Backed Precision Diagnostics Firm Amwise Raises $10M in Series B Funding Round

According to dealstreetasia.com, Amwise Diagnostics Pte. Ltd. ("Amwise"), an oncology precision diagnosis firm, has secured $10 million in its Series B funding round led by China's Jiangsu Simcere Medical Diagnosis ("Simcere Diagnosis"), per a company announcement. Proceeds of this financing will mainly be used to promote the Asian breast cancer recurrence risk assessment and detection project -- RecurIndex^® in the Chinese market.

Amwise had completed its Series A round funding from Alibaba Entrepreneurs Fund, US cross-border venture firm WI Harper and Indonesian real estate developer Lippo Group back in 2016.  

Amwise offers novel precision diagnosis solutions for cancer patients. Based on Asian genes, the company has developed a proprietary pipeline for breast cancer diagnosis. RecurIndex^®, which has undergone large-scale clinical validation, integrates genetic mapping of the genes most related to breast cancer recurrence in Asian patients with clinical factors to predict the 5-year risk of local recurrence and distant metastasis. The test results can help doctors and patients have an earlier understanding of cancer characteristics and can serve as an important reference in the determination of appropriate treatment. 

In 2019, Amwise reached strategic cooperation with Simcere Diagnosis. In virtue of the cooperation, Amwise took the lead in forming the business model of "pharmaceutical industry + diagnosis" in China to promote the development of China's molecular diagnosis market.

Headquartered in Taipei, Amwise has a branch in Singapore and a subsidiary in Hangzhou.

Founded by Simcere Pharmaceutical Group in 2017, Simcere Diagnostics is a precision medicine company based in China and led by a team of highly experienced professionals in medical genomics and informatics. Utilizing various state-of-the-art technology platforms including Next Generation Sequencing, Nanopore sequencing, MassARRAY^® genotyping, digital PCR, as well as advanced bioinformatics, Simcere Diagnostics is committed to fulfilling the unmet medical needs in disease diagnosis, treatment guidance, and progress monitoring via cost-effective and personalized solutions. 

Simcere Diagnostics is dedicated to developing cutting-edge diagnostic products in the clinical areas of cancer, central nervous system diseases, infectious diseases, pharmacogenomics, and autoimmune disorders.